Journal of the American Society of Nephrology, Vol 9, 224-230, Copyright © 1998 by American Society of Nephrology

REGULAR ARTICLES

Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation

M Ots, HS Mackenzie, JL Troy, HG Rennke and BM Brenner
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rate of progression of experimental renal disease. Although the end result of both classes of drugs is to block the renin-angiotensin system (RAS), ACEI and AT1RA act at different sites in the RAS cascade. The aim of this study was to compare the effects of an ACEI (enalapril) and AT1RA (losartan), alone or in combination, in slowing the progression of experimental renal disease in a model of reduced renal mass. Two weeks after 5/6 renal ablation, rats were divided into five groups matched for body weight, systolic BP (SBP), and urinary protein excretion rate (UprotV). The effects on SBP and UprotV of treatment with 25 and 40 mg/L enalapril (groups I and II; both n = 7), 180 mg/L losartan (group III, n = 8), or a combination of enalapril (25 mg/L) + losartan (180 mg/L) (group IV, n = 9) versus vehicle (group V, n = 9) were studied for 12 wk. Remnant kidneys were then assessed histologically for evidence of focal and segmental glomerulosclerosis and hyalinosis (FSGS), and interstitial fibrosis. There were no significant differences (NSD) in body weight among the groups at any time. Combination therapy reduced SBP (122 +/- 8 mmHg) significantly at 12 wk to levels similar to losartan (127 +/- 3 mmHg) or enalapril (40 mg/L) alone (124 +/- 5 mmHg) (P < 0.05 versus vehicle controls). With equivalent antihypertensive effects, no differences in frequency of FSGS were discerned among the treatment groups (groups II through IV; F = 1.7, NSD). Tubulointerstitial injury scores followed a similar pattern. BP was highly correlated with the extent of FSGS, both among individual rats (r = 0.68, P = 0.05) and the group means (r = 0.99, P = 0.001). We conclude that the renoprotective effects of enalapril, losartan, or combination therapy are similar in this model over the 12 wk of the study, and are closely related to the magnitude of their antihypertensive effects.

This article has been cited by other articles:

				H. Y. Li, F. F. Hou, X. Zhang, P. Y. Chen, S. X. Liu, J. X. Feng, Z. Q. Liu, Y. X. Shan, G. B. Wang, Z. M. Zhou, et al. Advanced Oxidation Protein Products Accelerate Renal Fibrosis in a Remnant Kidney Model J. Am. Soc. Nephrol., February 1, 2007; 18(2): 528 - 538. [Abstract] [Full Text] [PDF]

				K. A. Griffin and A. K. Bidani Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065. [Abstract] [Full Text] [PDF]

				V Teplitsky, Y Shoenfeld, and A Tanay The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans Lupus, June 1, 2006; 15(6): 319 - 325. [Abstract] [PDF]

				P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]

				M. Rook, A. T. Lely, A. B. Kramer, H. van Goor, and G. Navis Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage Nephrol. Dial. Transplant., January 1, 2005; 20(1): 59 - 64. [Abstract] [Full Text] [PDF]

				A. Erman, S. Veksler, U. Gafter, G. Boner, C. Wittenberg, and D. J. van Dijk Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor {beta}1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 146 - 151. [Abstract] [PDF]

				M. Azizi and J. Menard Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists Circulation, June 1, 2004; 109(21): 2492 - 2499. [Full Text] [PDF]

				P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999. [Abstract] [Full Text] [PDF]

				M. Sabbatini, A. Pisani, F. Uccello, G. Fuiano, R. Alfieri, A. Cesaro, B. Cianciaruso, and V. E. Andreucci Arginase inhibition slows the progression of renal failure in rats with renal ablation Am J Physiol Renal Physiol, April 1, 2003; 284(4): F680 - F687. [Abstract] [Full Text] [PDF]

				C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF]

				K. Amann, A. Simonaviciene, T. Medwedewa, A. Koch, S. Orth, M.-L. Gross, C. Haas, A. Kuhlmann, W. Linz, B. Scholkens, et al. Blood Pressure-Independent Additive Effects of Pharmacologic Blockade of the Renin-Angiotensin and Endothelin Systems on Progression in a Low-Renin Model of Renal Damage J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2572 - 2584. [Abstract] [Full Text] [PDF]

				M. W. TAAL, V. D. NENOV, W. WONG, S. R. SATYAL, O. SAKHAROVA, J. H. CHOI, J. L. TROY, and B. M. BRENNER Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2051 - 2059. [Abstract] [Full Text] [PDF]

				N. A. BOBADILLA, I. TACK, E. TAPIA, L. G. SANCHEZ-LOZADA, J. SANTAMARIA, F. JIMENEZ, L. J. STRIKER, G. E. STRIKER, and J. HERRERA-ACOSTA Pentosan Polysulfate Prevents Glomerular Hypertension and Structural Injury Despite Persisting Hypertension in 5/6 Nephrectomy Rats J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2080 - 2087. [Abstract] [Full Text] [PDF]

				J. L. Wilkinson-Berka, N. J. Gibbs, M. E. Cooper, S. L. Skinner, and D. J. Kelly Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1343 - 1349. [Abstract] [Full Text] [PDF]

				Y. Nakamura, H. Ono, X. Zhou, and E. D. Frohlich Angiotensin Type 1 Receptor Antagonism and ACE Inhibition Produce Similar Renoprotection in N{{omega}}-Nitro-L>-Arginine Methyl Ester/Spontaneously Hypertensive Rats Hypertension, May 1, 2001; 37(5): 1262 - 1267. [Abstract] [Full Text] [PDF]

				K. A Griffin, M. M Picken, G. Bakris, and A. K Bidani Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S191 - S195. [Abstract] [PDF]

				T. Morgan Review: Effect of combining angiotensin receptor blockers and ACE inhibitors on cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S223 - S226. [PDF]

				M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]

				M. W. Taal, G. M. Chertow, H. G. Rennke, A. Gurnani, T. Jiang, A. Shahsafaei, J. L. Troy, B. M. Brenner, and H. S. Mackenzie Mechanisms underlying renoprotection during renin-angiotensin system blockade Am J Physiol Renal Physiol, February 1, 2001; 280(2): F343 - F355. [Abstract] [Full Text] [PDF]

				E. Turkstra, B. Braam, and H. A. Koomans Normal TGF Responsiveness During Chronic Treatment With Angiotensin-Converting Enzyme Inhibition : Role of AT1 Receptors Hypertension, November 1, 2000; 36(5): 818 - 823. [Abstract] [Full Text] [PDF]

				Z. Cao, M. E. Cooper, L. L. Wu, A. J. Cox, K. Jandeleit-Dahm, D. J. Kelly, and R. E. Gilbert Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury Hypertension, October 1, 2000; 36(4): 561 - 568. [Abstract] [Full Text] [PDF]

				M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]

				D. Z. Levine, M. Iacovitti, B. Luck, M. T. Hincke, K. D. Burns, and J. N. Fryer Surviving rat distal tubule bicarbonate reabsorption: effects of chronic AT1 blockade Am J Physiol Renal Physiol, March 1, 2000; 278(3): F476 - F483. [Abstract] [Full Text] [PDF]

				G. REMUZZI, C. ZOJA, E. GAGLIARDINI, D. CORNA, M. ABBATE, and A. BENIGNI Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1542 - 1549. [Abstract] [Full Text]

				F. C. Luft, E. Mervaala, D. N. Muller, V. Gross, F. Schmidt, J. K. Park, C. Schmitz, A. Lippoldt, V. Breu, R. Dechend, et al. Hypertension-Induced End-Organ Damage : A New Transgenic Approach to an Old Problem Hypertension, January 1, 1999; 33(1): 212 - 218. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673